STOCK TITAN

[6-K] Haleon plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Haleon plc announces it purchased 2,875,831 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,963,475,311 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,959,595,106 ordinary shares with voting rights. A full breakdown of the individual trades is provided via the linked RNS PDF and will also be available on the Company's investor website. The announcement clarifies it does not constitute an offer for securities.

Haleon plc comunica di aver acquistato 2.875.831 azioni ordinarie da £0,01 ciascuna da cancellare, nell'ambito della seconda tranche del programma di riacquisto di azioni annunciato il 31 luglio 2025. A seguito del regolamento, il capitale sociale registrato è pari a 8.963.475.311 azioni ordinarie, di cui 3.880.205 sono detenute come azioni in tesoreria, lasciando 8.959.595.106 azioni ordinarie con diritto di voto. La ripartizione dettagliata delle singole operazioni è disponibile nel PDF RNS collegato e sul sito web per gli investitori della Società. La comunicazione precisa che non costituisce un'offerta di strumenti finanziari.

Haleon plc anuncia que ha comprado 2.875.831 acciones ordinarias de £0,01 cada una para su cancelación, en la segunda tanda de su programa de recompra de acciones anunciado el 31 de julio de 2025. Tras la liquidación, el capital social registrado asciende a 8.963.475.311 acciones ordinarias, de las cuales 3.880.205 se mantienen en autocartera, quedando 8.959.595.106 acciones ordinarias con derecho a voto. El desglose completo de las operaciones individuales se proporciona en el PDF RNS enlazado y también estará disponible en la web de inversores de la Compañía. El anuncio aclara que no constituye una oferta de valores.

Haleon plc는 2025년 7월 31일 발표된 자사주 매입 프로그램의 두 번째 트랜치에서 소멸을 위해 2,875,831주의 액면가 £0.01 보통주를 취득했다고 발표했습니다. 결제 완료 후 등록된 납입자본은 8,963,475,311주 보통주이며, 이 중 3,880,205주는 자사주로 보유되어 투표권이 있는 보통주는 8,959,595,106주입니다. 개별 거래의 전체 내역은 연결된 RNS PDF에서 확인할 수 있으며 회사 투자자 웹사이트에도 게재될 예정입니다. 본 발표는 증권에 대한 청약(오퍼)을 구성하지 않음을 명확히 합니다.

Haleon plc annonce avoir acheté 2 875 831 actions ordinaires de £0,01 chacune en vue de leur annulation, dans le cadre de la deuxième tranche de son programme de rachat d'actions annoncé le 31 juillet 2025. Après règlement, le capital social enregistré s'élève à 8 963 475 311 actions ordinaires, dont 3 880 205 sont détenues en actions propres, laissant 8 959 595 106 actions ordinaires avec droit de vote. La ventilation complète des opérations individuelles est fournie dans le PDF RNS lié et sera également disponible sur le site investisseurs de la Société. L'annonce précise qu'elle ne constitue pas une offre de titres.

Haleon plc gibt bekannt, dass es im Rahmen der zweiten Tranche seines am 31. Juli 2025 angekündigten Aktienrückkaufprogramms 2.875.831 Stammaktien zu je £0,01 zum Zwecke der Vernichtung erworben hat. Nach Abschluss der Abwicklung beträgt das eingetragene Grundkapital 8.963.475.311 Stammaktien, davon werden 3.880.205 als eigene Aktien gehalten, sodass 8.959.595.106 stimmberechtigte Stammaktien verbleiben. Eine vollständige Aufschlüsselung der Einzeltransaktionen finden Sie im verlinkten RNS-PDF und auf der Investorenseite des Unternehmens. Die Mitteilung stellt klar, dass sie kein Angebot von Wertpapieren darstellt.

Positive
  • Share buyback executed: Purchase of 2,875,831 ordinary shares completed for cancellation under the second tranche of the programme
  • Updated share counts provided: Registered share capital, treasury shares, and voting shares are disclosed to inform shareholder notification obligations
  • Trade-level transparency: Full breakdown of individual trades made available via RNS PDF and the Company website
Negative
  • None.

Insights

TL;DR: Company executed a share buyback cancellation of 2,875,831 shares and updated its issued and voting share totals.

Haleon completed purchases of 2,875,831 ordinary shares for cancellation as part of the second tranche of a previously announced buyback programme. The filing reports updated registered share capital and the number of treasury shares, and provides a link to a full trade breakdown. The disclosure is routine and compliant with market abuse rules, supplying necessary figures shareholders use to assess notification thresholds under the FCA's rules.

TL;DR: Formal notification of share cancellation and updated share counts ensures transparency for shareholder reporting obligations.

The company furnishes the transaction details required by Article 5(1)(b) of the Market Abuse Regulation and states where the trade-level data can be accessed. The filing updates the official share register counts and clarifies the number of voting shares, which is material for shareholders determining notification requirements under the FCA Disclosure Guidance and Transparency Rules.

Haleon plc comunica di aver acquistato 2.875.831 azioni ordinarie da £0,01 ciascuna da cancellare, nell'ambito della seconda tranche del programma di riacquisto di azioni annunciato il 31 luglio 2025. A seguito del regolamento, il capitale sociale registrato è pari a 8.963.475.311 azioni ordinarie, di cui 3.880.205 sono detenute come azioni in tesoreria, lasciando 8.959.595.106 azioni ordinarie con diritto di voto. La ripartizione dettagliata delle singole operazioni è disponibile nel PDF RNS collegato e sul sito web per gli investitori della Società. La comunicazione precisa che non costituisce un'offerta di strumenti finanziari.

Haleon plc anuncia que ha comprado 2.875.831 acciones ordinarias de £0,01 cada una para su cancelación, en la segunda tanda de su programa de recompra de acciones anunciado el 31 de julio de 2025. Tras la liquidación, el capital social registrado asciende a 8.963.475.311 acciones ordinarias, de las cuales 3.880.205 se mantienen en autocartera, quedando 8.959.595.106 acciones ordinarias con derecho a voto. El desglose completo de las operaciones individuales se proporciona en el PDF RNS enlazado y también estará disponible en la web de inversores de la Compañía. El anuncio aclara que no constituye una oferta de valores.

Haleon plc는 2025년 7월 31일 발표된 자사주 매입 프로그램의 두 번째 트랜치에서 소멸을 위해 2,875,831주의 액면가 £0.01 보통주를 취득했다고 발표했습니다. 결제 완료 후 등록된 납입자본은 8,963,475,311주 보통주이며, 이 중 3,880,205주는 자사주로 보유되어 투표권이 있는 보통주는 8,959,595,106주입니다. 개별 거래의 전체 내역은 연결된 RNS PDF에서 확인할 수 있으며 회사 투자자 웹사이트에도 게재될 예정입니다. 본 발표는 증권에 대한 청약(오퍼)을 구성하지 않음을 명확히 합니다.

Haleon plc annonce avoir acheté 2 875 831 actions ordinaires de £0,01 chacune en vue de leur annulation, dans le cadre de la deuxième tranche de son programme de rachat d'actions annoncé le 31 juillet 2025. Après règlement, le capital social enregistré s'élève à 8 963 475 311 actions ordinaires, dont 3 880 205 sont détenues en actions propres, laissant 8 959 595 106 actions ordinaires avec droit de vote. La ventilation complète des opérations individuelles est fournie dans le PDF RNS lié et sera également disponible sur le site investisseurs de la Société. L'annonce précise qu'elle ne constitue pas une offre de titres.

Haleon plc gibt bekannt, dass es im Rahmen der zweiten Tranche seines am 31. Juli 2025 angekündigten Aktienrückkaufprogramms 2.875.831 Stammaktien zu je £0,01 zum Zwecke der Vernichtung erworben hat. Nach Abschluss der Abwicklung beträgt das eingetragene Grundkapital 8.963.475.311 Stammaktien, davon werden 3.880.205 als eigene Aktien gehalten, sodass 8.959.595.106 stimmberechtigte Stammaktien verbleiben. Eine vollständige Aufschlüsselung der Einzeltransaktionen finden Sie im verlinkten RNS-PDF und auf der Investorenseite des Unternehmens. Die Mitteilung stellt klar, dass sie kein Angebot von Wertpapieren darstellt.

 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
28 August 2025 - Transaction in Own Shares
 
 
99.1
 
 
 
 
 
Haleon plc: Transaction in own shares
  
28 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 2,875,831 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.
 
 
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Date of purchase:
27 August 2025
27 August 2025
27 August 2025
Number of Shares purchased:
2,875,831
-
-
Highest price paid per Share (p):
363.7000
-
-
Lowest price paid per Share (p):
359.2000
-
-
Volume weighted average price paid per Share (p):
361.3796
-
-
 
Following the settlement of the above, the Company's registered share capital is 8,963,475,311 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,959,595,106 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
  
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/9460W_1-2025-8-27.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
  
Enquiries
 
 
Investors
Media
 
Jo Russell  
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
 
About Haleon
 
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: August 28, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary
 
 
 

FAQ

What shares did Haleon (HLN) purchase in this announcement?

Haleon purchased 2,875,831 ordinary shares of £0.01 each for cancellation under the second tranche of its buyback programme.

How many ordinary shares with voting rights does Haleon have after this transaction?

After settlement, there are 8,959,595,106 ordinary shares with voting rights.

How many treasury shares does Haleon hold following the cancellation?

The Company holds 3,880,205 shares as treasury shares.

Where can I find the full breakdown of the individual trades?

A full breakdown is available at the provided RNS PDF link and on the Company's investor website: www.haleon.com/investors.

Does this announcement constitute an offer for securities?

No. The announcement states it does not constitute, or form part of, an offer or solicitation for securities in any jurisdiction.
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

43.17B
4.48B
0.02%
12.82%
0.39%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge